Latest profit margin for NewAmsterdam Pharma Company NV: -789.94% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
NewAmsterdam Pharma Company NV (NAMS) currently reports a profit margin of -789.94% as of September 2026. That compares with -627.28% in the prior-year period — down 25.9% year over year. That is below the sector sector average of 13.4%. Use the charts on this page to explore NewAmsterdam Pharma Company NV's profit margin history and peer comparisons.
NewAmsterdam Pharma Company NV's profit margin decreased from -627.28% to -789.94% — a 25.9% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
NewAmsterdam Pharma Company NV's profit margin of -789.94% is lower than the its sector sector average of 13.4%. That is roughly 5993.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but NewAmsterdam Pharma Company NV's current -789.94% should be judged against industry norms (sector average: 13.4%) and against NAMS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -789.94%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.4%. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.